News about Clinical Trials

SMC unveils Cambridge Pharma

SMC unveils Cambridge Pharma

The new business will offer pharmaceutical development services, including sterile fill-finish

Clinical Trials | 07/09/2022 | By Sudeep Soparkar 129

3D model created for rare neuromuscular disorder

3D model created for rare neuromuscular disorder

Scientists have created a bioengineered 3-D model that mimics the biology of two rare diseases. The researchers used the 'tissue chip' model to show how a drug could potentially treat the diseases, providing data for a drug company's FDA submission for authorization for clinical testing.

Clinical Trials | 04/05/2022 | By Sudeep Soparkar 196

New patent grant to OSE Immunotherapeutics by EPO

New patent grant to OSE Immunotherapeutics by EPO

OSE Immunotherapeutics receives European patent covering novel myeloid immune checkpoint target, CLEC-1 for cancer treatment

Clinical Trials | 03/05/2022 | By Sudeep Soparkar 133

EMA reviews gene therapy for Haemophilia B

EMA reviews gene therapy for Haemophilia B

EMA (European Medicines Agency) has started reviewing the CSL Behring's MAA for gene therapy etranacogene dezaparvovec (EtranaDez), for the patients getting treatment for Haemophila B.

Clinical Trials | 28/04/2022 | By Sudeep Soparkar 178

ALS drug by Biogen and Ionis Pharmaceuticals fails in trials

ALS drug by Biogen and Ionis Pharmaceuticals fails in trials

Biogen and Ionis Pharmaceuticals were hoping to be the first to find a cure for ALS. That dream has now fizzled out with the companies calling it quits after receiving disappointing results from a phase 1 clinical trial.

Clinical Trials | 27/04/2022 | By Sudeep Soparkar 129

Anti-Tigit drug of Roche fails stage study

Anti-Tigit drug of Roche fails stage study

Roche's Genentech had disappointing news to share this week regarding its lung cancer hopeful.

Clinical Trials | 26/04/2022 | By Sudeep Soparkar 126

Funds of $130m raised for B cell medications

Funds of $130m raised for B cell medications

Be Bio raises $130m to foster designed B cell medications. As a feature of the financing, ARCH Venture Partners overseeing chief Steven Gillis will join Be Bio's governing body.

Clinical Trials | 23/04/2022 | By Sudeep Soparkar 115

BioXcel to develop drugs in oncology

BioXcel to develop drugs in oncology

BioXcel shapes entirely claimed auxiliary OnkosXcel to foster prescriptions centered in oncology

Clinical Trials | 21/04/2022 | By Sudeep Soparkar 120

IDB therapies to improve with lymphoid cell maturity

IDB therapies to improve with lymphoid cell maturity

New knowledge on lymphoid cell maturity could lead to more effective IBD therapies

Clinical Trials | 18/04/2022 | By Sudeep Soparkar 205

Effects of rilzabrutinib in individuals with insusceptible thrombocytopenia

Effects of rilzabrutinib in individuals with insusceptible thrombocytopenia

Positive phase 1/2 study results of rilzabrutinib in people with immune thrombocytopenia published in The New England Journal of Medicine

Clinical Trials | 16/04/2022 | By Sudeep Soparkar 188

 
 

 

 

We use our own and third party cookies to produce statistical information and show you personalized advertising by analyzing your browsing, according to our COOKIES POLICY. If you continue visiting our Site, you accept its use.

More information: Privacy Policy

 pharmaindustrial-india.com - Professional magazine for pharma industry suppliers and lab technology